Abstract
Objective
To compare the relative levels of connective tissue growth factor (CTGF), platelet-derived growth factor alpha (PDGF-AA), and hepatocyte growth factor (HGF) in glial and retinal pigment epithelial (RPE) cells of epiretinal membranes from proliferative vitreoretinopathy (PVR).
Methods
A total of 37 PVR membranes, of various stages, underwent fluorescent immunohistochemisty and confocal laser scanning microscopy to localize CTGF, HGF, and PDGF-AA in RPE and glial cells.
Results
Numerous RPE, and relatively fewer glial cells, were found in all stages of PVR. CTGF immunoreactivity increased from early to late stage PVR and was principally expressed by RPE cells in early stage, and by glial cells in late stage PVR. HGF, expressed by both RPE and glial cells, was principally expressed in mid-stage PVR. PDGF-AA, expressed by both cell types, demonstrated a uniform level of staining throughout all stages of PVR.
Conclusions
RPE and glial cells contribute to the expression of CTGF, HGF, and PDGF-AA during PVR, but with specific developmental patterns. PDGF-AA is expressed uniformly throughout all stages of PVR, while HGF expression peaks during mid stage, and CTGF expression is highest during late stage PVR. These results allow for the development of stage-specific therapeutics for PVR that may allow targeting of the early proliferative and/or the late tractional stages of PVR.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121–125.
Garcia-Arumi J, Corcostegui B, Tallada N . Subretinal membranes in proliferative vitreoretinopathy. An immunohistochemical study. Retina 1992; 12(3 Suppl): S55–S59.
Hiscott P, Morino I, Alexander R, Grierson I, Gregor Z . Cellular components of subretinal membranes in proliferative vitreoretinopathy. Eye 1989; 3: 606–610.
Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL, Grierson I . Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology 1993; 100(1): 43–46.
Charteris DG . Growth factors in proliferative vitreoretinopathy. Br J Ophthalmol 1998; 8(2): 106.
Hinton DR, He S, Jin ML, Barron E, Ryan SJ . Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 2002; 16(4): 422–428.
Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994; 35(10): 3649–3663.
Rosenkranz S, Kazlauskas A . Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999; 16: 201–216.
Liang Y, Li X, Fan J, Zhao M, Jiang Y . The effect of platelet-derived growth factor on the formation of proliferative vitreoretinopathy. Zhonghua Yan Ke Za Zhi 2002; 38(3): 144–147.
Fenton H, Finch PW, Rubin JS, Rosenberg JM, Taylor WG, Kuo-Leblanc V et al. Hepatocyte growth factor (HGF/SF) in Alzheimer's disease. Brain Res 1998; 779(1–2): 262–270.
Grotendorst GR, Rahmanie H, Duncan MR . Combinational signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 2004; 18(3): 469–479.
Heldin CH, Ostman A, Ronnstrand L . Signal transduction via platelet-derived growth factor receptors. Biochem Biophys Acta 1998; 1378: F79–F113.
Andrews A, Balciunaite E, Leong FL, Tallquist M, Soriano P, Refojo M et al. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Opthalmol Vis Sci 1999; 40(11): 2683–2689.
Lashkari K, Rahimi N, Kazlauskas A . Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1999; 40(1): 149–156.
He PM, He S, Garner JA, Ryan SJ, Hinton DR . Retinal pigment epithelial cells secrete and respond to hepatocyte growth factor. Biochem Biophys Res Commun 1998; 249: 253–257.
Surveyor GA, Brigstock DR . Immunohistochemical localization of connective tissue growth factor in the mouse embryo between days 7.5 and 14.5 of gestation. Growth Factors 1999; 17(2): 255–260.
Zhang L, Himi T, Murota S . Induction of hepatocyte growth factor (HGF) in rat microglial cells by prostaglandin E (2). J Neuosci Res 2000; 62(3): 389–395.
Brigstock DR . The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999; 20: 189–206.
Perbal B . CCN proteins: multifunctional signalling regulators. Lancet 2004; 363(9402): 62–64.
Gao R, Brigstock DR . Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem 2004; 279(10): 8848–8855.
Moussad EE, Brigstock DR . Connective tissue growth factor: what's in a name? Mol Genet Metab 2000; 71(1–2): 276–292.
Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ . TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000; 41(8): 2336–2342.
Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, Baker J et al. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol Vis 2002; 8: 494–501.
Hollborn M, Krausse C, Iandiev I, Yafai Y, Tenckhoff S et al. Glial cell expression of hepatocyte growth factor in vitreoretinal proliferative disease. Lab Invest 2004; 84(8): 963–972.
Jin ML, Chen YX, He SK, Ryan JS, Hinton DR . Hepatocyte growth factor and its role in the pathogenesis of retinal detachment. Invest Ophthalmol Vis Sci 2004; 45: 323–329.
Zanegar R, Michalopoulos GK . The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995; 129: 1177–1180.
Matsumoto K, Nakamura T . Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996; 119: 591–600.
Boros P, Miller CM . Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995; 353: 293–295.
Jin M, Barron E, He S, Ryan SJ, Hinton DR . Regulation of RPE intercellular junction integrity and function by hepatocyte growth factor. Invest Ophthalmol Vis Sci 2002; 43(8): 2782–2790.
Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S . Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol 1998; 82: 181–185.
Briggs MC, Grierson I, Hiscott P, Hunt JA . Active scatter factor (HGF/SF) in proliferative vitreoretinal disease. Invest Ophthalmol Vis Sci 2000; 41: 3085–3094.
Ikuno Y, Leong FL, Kazlauskas A . Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci 2000; 41: 3107–3116.
Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E et al. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci 2002; 43: 2001–2006.
Planck SR, Andresevic J, Chen JC, Holmes DL, Rodden W, Westra I et al. Expression of growth factor mRNA in rabbit PVR model systems. Curr Eye Res 1992; 11(11): 1031–1039.
Weller M, Heimann K, Wiedemann P . Mononuclear phagocytes and their growth factors: pacemakers of proliferative vitreoretinopathy? Klin Monatsbl Augenheilkd 1990; 196(3): 121–127.
Kirchhof B . Strategies to influence PVR development. Graege's Arch Clin Exp Ophthamol 2004; 242: 699–703.
Wiedemann P, Hilgers RD, Bauer P, Heimann K . Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 1998; 126(4): 550–559.
Allinson RW . Adjuvant 5-FU and heparin prevent PVR. Ophthalmology 2002; 109: 829–830.
Lemor M, Yeo JH, Glaser BM . Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol 1986; 104: 1226–1229.
van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ . Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1985; 26: 1140–1147.
Binder S, Bonnet M, Velikay M, Gerard JP, Stolba U, Wedrich A et al. Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study. Graefes Arch Clin Exp Ophthalmol 1994; 232: 211–214.
Mandava N, Blackburn P, Paul DB, Wilson MW, Read SB, Alspaugh E et al. Ribozyme to proliferating cell nuclear Aantigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2002; 43: 3338–3348.
Acknowledgements
The authors acknowledge Allison L Ning and Eleanor C. To, who assisted in the data collection during the course of this study. Supported by Canadian Institutes of Health Research Grant MOP 42389.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cui, J., Chiu, A., Maberley, D. et al. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye 21, 200–208 (2007). https://doi.org/10.1038/sj.eye.6702169
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702169
Keywords
This article is cited by
-
TSPAN4-positive migrasome derived from retinal pigmented epithelium cells contributes to the development of proliferative vitreoretinopathy
Journal of Nanobiotechnology (2022)
-
Proliferative Vitreoretinopathie-Prozess – „To heal or not to heal“
Der Ophthalmologe (2021)
-
The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study
BMC Ophthalmology (2020)
-
Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and review
International Ophthalmology (2020)
-
Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy
Eye (2017)
